Inclusion Criteria:

- Histologically or cytologically confirmed malignant mesothelioma (MM)

- Have received only one prior systemic chemotherapy platinum-based regimen for
advanced MM

- Disease not amenable to curative surgery

- No known brain metastasis

- Age 18 and over

- Performance status 0-2

- Life expectancy > 12 weeks

- Adequate hematologic, hepatic and renal function

- Not pregnant or nursing

- Patient must be willing and able to provide written informed consent, and the trial
have to be approved by the institutional review board at each institution

Exclusion Criteria:

- Symptomatic chronic inflammatory or autoimmune disease

- Active hepatitis B or C

- Clinically relevant cardiovascular disease, i.e., myocardial infarction or other
severe coronary artery diseases within the prior 6 months, cardiac arrythmia
requiring medication, uncontrolled hypertension, overt cardiac failure or not
compensated chronic heart disease in NYHA class II or more

- History of psychiatric disabilities, potentially interfering with the capability of
giving adequate informed consent

- Uncontrolled active infections

- Other concurrent chemotherapy, immunotherapy, radiotherapy or investigational agents

- History of other malignancies except for adequately treated basal cell carcinoma or
squamous cell skin cancer or carcinoma of cervix, unless the patient has been
disease-free for at least 5 years